Perdigones IDRA-21 de 10 mg
IDRA-21 Pellets properties
Sinónimo : 1,1-dióxido de 7-cloro-3-metil-3,4-dihidro-2H-1,2,4-benzotiadiazina
CAS Número : 22503-72-6
Fórmula :C8H9ClN2O2S
Masa molar :232,6 g/mol
Pureza : >97%
€13.50 - €398.58Rango de precios: desde €13.50 hasta €398.58
* La información de esta página es un resumen y no pretende abarcar toda la información disponible sobre este medicamento. No abarca todos los posibles usos, instrucciones, precauciones, interacciones farmacológicas ni efectos adversos, ni sustituye la experiencia y el criterio de su profesional de la salud.
IDRA-21 10 MG Pellets – Scientific Description & User Manual
Descripción del Producto
IDRA-21 (gránulos de 10 mg) is a potential AMPA receptor potentiator belonging to the class of nootropic and neuroprotective research chemicals . It works by enhancing glutamate-induced signaling in the brain, which may lead to improved cognitive function, neuroplasticity, and potentially neurorecovery.
These pellets are highly pure (≥98%) , standardized dosed and intended solely for scientific research and preclinical studies .
Uses & Applications
IDRA-21 is being studied for its possible effects on:
Cognitive Enhancement – May increase alertness, learning ability, and memory consolidation.
Neuroprotection – Potential protective effect in neurodegenerative diseases (e.g. Alzheimer’s, stroke).
Neurological Recovery – May Promote Synaptic Plasticity After Brain Injury.
Investigación científica – Study of AMPA receptor modulation and glutamate signaling.
⚠ Not approved for human or veterinary use – For in vitro and controlled preclinical studies only.
Dosage & Safety Guidelines
Investigational dosage (in vitro/preclinical): 5–20 mg/kg (depending on model).
Pellet Solution: Can be dissolved in distilled water or DMSO for experiments.
Administración: Orally (animal models) or directly in cell cultures.
Frecuencia: Single dose for acute effect; long-term studies require careful monitoring.
🚨 NB:
No human application – No safety data for human use.
High doses may cause neuroexcitotoxicity.
Avoid combination with other glutamate modulators.
Desventajas y riesgos
Overstimulation of neurons (risk of excitotoxicity in case of overdose).
Possible anxiety or agitation in susceptible models.
Limited long-term data on tolerance and adverse effects.
Not suitable for chronic use without extensive toxicity studies.
Preguntas frecuentes (FAQ)
1. Is IDRA-21 legal in the Netherlands?
Yes, but only for investigación científica . It doesn’t fall under the Opium Act, but it’s also not approved as a medicine.
2. How exactly does IDRA-21 work?
It enhances the AMPA receptor response , making glutamate signaling longer and more intense. This can lead to improved synaptic communication.
3. Can IDRA-21 be compared to other nootropics?
It has a unique mechanism of action, but similar targets as racetams or ampakines (e.g. Sunifiram).
4. Are there any known interactions?
NMDA antagonists (e.g. memantine) – Potentially adverse effects.
GABAergic agents (e.g., benzodiazepines) – May reduce anxiolytic effects.
Informe de laboratorio y control de calidad
HPLC analysis: ≥98% purity .
No detectable heavy metals or solvent residues .
Homogeneous pellet formulation for consistent dosing.
Batch certification available for research institutions.
Recommended Research Scenarios
Cognitive studies – Effects on memory and learning in animal models.
Neuroprotective research – Potential role in ischemic injury (stroke models).
Electrofisiología – AMPA receptor response measurements in neuronal cultures.
🔬 For controlled laboratory use only – No recreational use!
